

primary studies - published RCT

Pancreatic enzyme replacement therapy for young cystic fibrosis patients.

Code: PM18718819 **Year:** 2009 **Date:** 2012

Author: Munck A

Study design (if review, criteria of inclusion for studies)

double-blind, randomized, placebo-controlled crossover study

Participants

44 CF patients (aged 7-19 y; 20 males)

Interventions

patients were randomly assigned to receive magnesium (n = 22; 300 mg/d) or placebo (n = 22) for 8 wk with a 4-wk washout period between trials. All patients were undergoing conventional treatment of CF.

Outcome measures

Long-term effect of oral magnesium supplementation on respiratory muscle strength by using manuvacuometry and the Shwachman-Kulczycki (SK) score. The experimental protocol included clinical evaluation, assessment of urinary concentration of magnesium, and manuvacuometric measurements [maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP)]. MIP was the primary outcome.

Main results

Urinary magnesium increased after the administration of magnesium (change: 36.38 mg/d after magnesium compared with 0.72 mg/d after placebo; P

Authors' conclusions

Oral magnesium supplementation helped improve both the SK score and respiratory muscle strength in pediatric patients with CF.

<http://dx.doi.org/10.1016/j.jcf.2008.07.003>

See also

J Cyst Fibros. 2009 Jan;8(1):14-8. Epub 2008 Aug 21.

Keywords

magnesium; Minerals; Supplementation; non pharmacological intervention - diet; pharmacological_intervention;